Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126584
Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Aim To assess the toxicity, tolerance, steroid-sparing capacity, effectiveness, and response rate to imatinib and dasatinib for the treatment of severe sclerotic chronic graft-vs-host disease (scGVHD). Methods This retrospective study analyzed 8 consecutive patients with severe refractory scGVHD who received salvage therapy with imatinib. Patients intolerant and/or refractory to imatinib received dasatinib treatment. Results 7 patients discontinued imatinib treatment (1 achieved complete response, 5 were resistant and/or intolerant, and 1 developed grade IV neutropenia) and 1 patient achieved prolonged partial response, but died due to an infectious complication while on treatment 5 patients started dasatinib treatment (3 achieved partial responses and discontinued dasatinib, 1 achieved a durable partial response, but died due to a consecutive rapid pulmonary cGVHD progression and 1 with stable disease discontinued treatment due to gastroenteric intolerance). The response rate (partial and/or complete responses) for severe scGVHD was 25% for imatinib and 60% for dasatinib. Conclusion In our series, dasatinib was better tolerated, safer, steroid-sparing, and had a low incidence of infectious complications, which suggests that it may be a more effective therapeutic alternative for patients with refractory scGVHD than imatinib. Treatment of scGVHD with effective antifibrotic drugs such as TKI, which block the kinase fibrotic pathway, may be a safe and effective therapeutic option, but further studies are needed to confirm our findings.
Matèries (anglès)
Citació
Citació
SÁNCHEZ ORTEGA, Isabel, PARODY, Rocío, SERVITJE BEDATE, Octavio, MUNIESA MONTSERRAT, Cristina, ARNAN, Montserrat, PATIÑO, Beatriz, SUREDA, Anna, DUARTE, Rafael. Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.. _Croatian Medical Journal_. 2016. Vol. 57, núm. 3, pàgs. 247-254. [consulta: 25 de febrer de 2026]. ISSN: 0353-9504. [Disponible a: https://hdl.handle.net/2445/126584]